EDUARDO
DÍAZ-RUBIO GARCÍA
Ikertzailea 2020-(e)ra arte
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaHospital Clínico Universitario Lozano Blesa -ko ikertzaileekin lankidetzan egindako argitalpenak (10)
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2019
2015
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2009
-
Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients
Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736
2008
-
Risk-reduction surgery in BRCA mutation carriers in a Spanish population: Adherence and results
Clinical and Translational Oncology, Vol. 10, Núm. 10, pp. 660-664
2005
-
The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families
Familial Cancer, Vol. 4, Núm. 2, pp. 183-186